Using Monocyte Distribution Width to Diagnose Sepsis in Patients with Other Health Issues
Monocyte Distribution Width (MDW): An Early Marker of Sepsis in Patients With Comorbidities
This study is testing if measuring Monocyte Distribution Width can help doctors quickly diagnose sepsis in patients with other health problems like kidney or heart issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 325 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hôpital Universitaire Sahloul Academic / other |
| Locations | 1 site (Sousse) |
| Trial ID | NCT06953154 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Monocyte Distribution Width (MDW) as an early biomarker for diagnosing sepsis in patients with comorbidities such as renal failure, heart failure, and COPD. The study focuses on patients admitted to the emergency department for decompensation related to these conditions, where timely diagnosis is critical due to the high mortality rates associated with sepsis. By measuring MDW, the researchers hope to improve diagnostic accuracy and facilitate prompt treatment initiation, addressing the challenges posed by nonspecific symptoms in complex cases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are admitted to the emergency department for decompensation of congestive heart failure, renal failure, or exacerbation of COPD.
Not a fit: Patients who have received antibiotic treatment in the past 7 days, pregnant women, children, and those with certain hematologic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of sepsis, potentially reducing mortality rates in vulnerable patient populations.
How similar studies have performed: Previous studies in Europe and America have shown promising results for MDW as a biomarker for early sepsis diagnosis, indicating that this approach has been tested with some success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged over 18 years admitted to the emergency department for decompensation of congestive heart failure or renal failure, or exacerbation of COPD. Exclusion Criteria: * Patients who received antibiotic treatment in the past 7 days, pregnant women, children, non-consenting patients, patients with a history of malignant hematologic disease, polytransfused patients or those who recently received a transfusion, and patients whose MDW was not reported due to ineffective monocyte counting.
Where this trial is running
Sousse
- Sahloul University Hospital — Sousse, Tunisia (Recruiting)
Study contacts
- Study coordinator: Boukef Riadh Professor
- Email: riadboukef@gmail.com
- Phone: +216 98676745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.